Editorial Board

Founding Editor in Chief
Prof. Xue-Zhong Yu, MD & MS

Prof. Xue-Zhong Yu, MD & MS
Professor
Dr. Robert Stuart Endowed Chair in Hematology/Oncology Chair in SmartState Cancer Stem Cell Biology & Therapy Program
Department of Microbiology & Immunology, Department of Medicine, Medical University of South Carolina (MUSC)
USA

  Biography :

Xue-Zhong Yu, MD, MS, is a Professor in Immunology and Hematology. Dr. Yu has his primary appointment in the Department of Microbiology and Immunology, and a secondary appointment in the Division of Hematology/Oncology in the Department of Medicine at Medical University of South Carolina (MUSC). He also holds the Robert Stuart distinguished endowed chair in Stem Cell Biology and Therapy supported by the SmartState Economic Excellence Programs. Dr. Yu’s research focuses on the biology of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) after allogeneic hematopoietic stem cell transplantation (HSCT). The ultimate goal of these studies is to prevent or treat GVHD while preserving GVL effect, which could greatly enhance the therapeutic potential of HSCT. Dr. Yu’s research is currently supported by four R01 grants from the National Institute of Health. Dr. Yu and his team have made significant contributions to understand how T-cell activation, costimulation and differentiation regulate GVHD development and GVL activity. While the focus and the ultimate goal remain the same, the current research in Dr. Yu’s laboratory also extends to the areas of micro-RNA regulation, metabolism and microbiota.

Biography
  Research Interest :

T-cell activation, costimulation and differentiation regulate GVHD development and GVL activity, micro-RNA regulation, metabolism and microbiota

Research Interest
Co- Editor in Chief
Dr. Chrystal Paulos

Dr. Chrystal Paulos
Associate Professor
Associate Professor and Endowed Peng Chair
Medical University of South Carolina Hollings Cancer Center
USA

  Biography :

Dr. Chrystal Paulos is an expert in basic and translational aspects of T cells in tumor immunity. T cell-based cancer immunotherapy has been her research focus for more than a decade. She trained as a postdoctoral fellow at the NIH with Dr. Nicholas Restifo, where her research focus was on understanding the mechanisms underlying the effective of host preconditioning prior to adoptive T cell tranfer thearapy, an approach that augments treatment outcome in melanoma patients. Her work was the first to sucessfully demonstrate a key role of mucosal inflammation (induced by lymphodepletion) on increasing the efficacy of transferred tumor-specific CD8+ T cells, leading to cures in mice with established melanoma. She also studied the role of IL-17 producing CD4+ and CD8+ T cells (Th1, Th17, Tc1 and Tc17 cells) in tumor immunity. She did her second postdoc with Dr. Carl June at the University of Pennsylvania, where she focused on engineering human Th17 cells to treat patients with cancer. Her work was the first to show that costimulatory molecules that activate human Th17 cells dramatically alter their functional fate and tumor activity.

Biography
  Research Interest :

In that past 4 years, Chrystal has been an Assistant Professor at the NCI designated Hollings Cancer Center at Medical University of South Carolina in Charleston, SC. Her established lab identifies signaling cues and cytokines that regulate human T cell activation and function for immunotherapies for cancer. She also studies how lymphodepletion regulates the antitumor activity of T cells and how to exploit these mechanisms to improve treatment outcomes in patients with advanced malignancies.

Research Interest
Editorial Board Member
Dr. Yi Zhang, MD, PhD

Dr. Yi Zhang, MD, PhD
Associate Professor
Associate Professor Fels Institute for Cancer Research & Molecular Biology Department of Microbiology & Immunology
Temple University School of Medicine
USA

  Biography :

Being a physician scientist, I spend most of my time performing basic and disease-oriented research. This provides me a great opportunity to extend my innate curiosity about the basic mechanisms of disease and explore the possibility of translating basic science discoveries into clinical applications. I had my graduate training (MD-PhD) at the laboratory of Dr. Kouji Matsushima from Tokyo University (Japan), where I acquired extensive experience with studying hematopoietic stem cell biology, dendritic cell biology and chemokine regulation of immune responses. From 1998 to 2003, I did my postdoctoral training at University of Pennsylvania, studying immunology for gene therapy, Hematopoietic stem cell transplantation biology, and pathophysiology of graft-versus-host disease (GVHD, a life-threatening complication after stem cell transplantation). From 2003, I became a research faculty at Penn, continuing my research in the field of stem cell transplantation. Since August 2007 when I became a tenure track Assistant Professor at the University of Michigan, I have developed a research program to investigate cellular and molecular mechanisms that regulate T-cell immune responses and graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). GVHD is a major cause of death and profound immune deficiency after allo-HSCT. New methods to control GVHD are urgently needed. My lab discovered the critical roles of Ezh2 (which is a chromatin-modifying enzyme) and Notch (which is a signaling molecule regulating gene expression) in regulating T-cell immune responses and GVHD. Our research findings have been published in Journal of Immunology (2008), Biology of Bone Marrow Transplantation (2010), PLOSE ONE (2011), Blood (2011), Blood (2012), Journal of Immunology (2013), Blood (2013) and Journal of Immunology (2014). To develop pharmacological approaches that can be translated into patients, I have established close collaboration with scientists both in the United States and other international institutions to assess the impact of newly discovered Ezh2 inhibitors in the modulation of inflammatory immune responses. My goal is to develop novel and clinically relevant approaches to improve the treatment of hematological malignancies. From 2014, I am fortunate to be recruited as Associated Professor (Tenure track) to Temple University to continue my academic career. I have been successfully applied for extramural grants for supporting our research. I am the principal investigator on several peer-reviewed research grants from national agencies. These include: 1) R01 from NIH (1R01CA172106-01); 2) Department of Defense (WB1XWH-11-1-0294); and 3) Scholar Award from ACS (RSG-10-161-01-LIB).In collaboration with Dr. Ivan Maillard (U-M),we have also successfully applied for Damon Runyon Rachleff Innovative Award, which is an extremely prestigious award to young investigators. With securing these research grants, my laboratoryhas made significant progress in studying mechanisms that control inflammatory immune responses, development of GVHD and induction of anti-leukemic activity after allo-HSCT. Besidesthose published papers mentioned above, we have additional four manuscripts in preparation and/or submission, including one in revision for Blood (2013). Upon publishing these studies, we plan to apply for more extramural research funding to support our research.

Biography
  Research Interest :

Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Targeting Ezh2 to modulate T cell immunity, Targeting Notch signaling to modulate alloimmunity

Research Interest
Dr. Xuefang Cao, MD, PhD

Dr. Xuefang Cao, MD, PhD
Associate Professor
Associate Professor of Oncology and Immunology
Roswell Park Cancer Institute, Buffalo, New York,
USA

  Biography :

Xuefang Cao, MD, PhD, is an Associate Professor of Oncology and Immunology at Roswell Park Cancer Institute. Dr. Cao’s scientific efforts have been directed toward understanding the complexities of T cell biology and how T cells contribute to tumor immunity and transplantation immunity. Dr. Cao’s lab has focused on investigating the cellular and molecular mechanisms governing T cell differentiation, activation and effector function in the setting of hematopoietic cell transplantation (HCT) for the treatment of blood cancers. Specifically, Dr. Cao and his colleagues are currently studying cancer patients and murine models in order to define the roles of costimulation pathways, adrenergic stress signaling, and cytotoxic molecules in T cell-mediated graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect. The long-term goal of their work is to exploit these pathways to develop novel therapeutic strategies that can improve immune-based therapies to benefit cancer patients.

Biography
  Research Interest :

Cancer immunology and immune-based cancer therapy, lymphocyte-mediated cytotoxicity,T cell costimulation and interaction with antigen-presenting cells, adrenergic stress signaling in T cell activation and function.

Research Interest
Dr. Shikhar Mehrotra, Ph.D

Dr. Shikhar Mehrotra, Ph.D
Associate Professor
Associate Scientific Director- Center of Cellular Therapy
Department of Surgery, Microbiology & Immunology Medical University of South Carolina Hollings Cancer Center
USA

  Biography :

Dr. Mehrotra is at Medical University of South Carolina at Charleston. He obtained his post-doctoral training at University of Connecticut Health Center after obtaining his Ph.D. in Immunology from Sanjay Gandhi Post Graduate Institute of Medical Sciences at Lucknow, India. Dr. Mehrotra's research is focused on understanding the molecular and metabolic pathways that get altered during T cell activation and expansion, primarily influencing T cell persistence. Further, Mehrotra lab uses differently programmed T cell subsets for immunotherapy of melanoma and vitiligo in in vivo models.

Biography
  Research Interest :

Activation Induced Cell Death (AICD) of a T cell, T cell development in immunity and tolerance, Identifying high affinity TCR for prostate cancer, elucidate role of cytokines in T cell persistence

Research Interest
Prof. Honglin Wang

Prof. Honglin Wang
Professor
Principal Investigator
Shanghai Institute of Immunology, Institute of Medical Sciences) Shanghai Jiao Tong University School of Medicine
China

  Biography :

Dr. Honglin Wang, is Professor of Special Appointment (Eastern Scholar) and Principle Investigator at Shanghai Jiao Tong University School of Medicine. From 2002 to 2006, Dr. Wang conducted his doctoral study in skin immunology and molecular medicine at Ulm University, Germany. In 2007, he received Outstanding Doctoral Dissertation Award (Summa Cum Laude) and Merck Serono Prize. After obtaining his Ph.D. degree, Dr. Wang continued working as a postdoctoral research associate at University of Ulm School of Medicine. Between 2002 and 2009, he participated in European collaborative research programs with Lund University at Sweden. Since 2009, Dr. Wang returned to China and established Laboratory of Skin Immunology at Shanghai Institute of Immunology, Institute of Medicine Sciences, Shanghai Jiao Tong University School of Medicine. Dr. Wang’s lab is focusing on skin stem cells, epigenetic regulation in T cell function and inflammatory skin diseases.

Biography
  Research Interest :

Skin stem cells, epigenetic regulation in T cell subset differentiation and the etiology of psoriasis.

Research Interest
Prof. Zhihai Qin

Prof. Zhihai Qin
Professor
Principal Investigator, Institute of Biophysics
Chinese Academy of Sciences
China

  Biography :

c. The manner of immune surveillance against tumor. For the majority of tumors that are induced by non-infectious inflammation, evidences are still lacking for the conventional theories of immune surveillance and immunogenic cell death (Nature Immunol, 2004). My group has done series of studies on mechanisms for anti-tumor immunity using the model of chemical carcinogen induced tumorigenesis. Our researches demonstrate that the repair of tissue injured by certain carcinogens in the host (foreign-body reaction) is another mechanism for immune surveillance against tumor. IFN inhibits the carcinogenesis by promoting this foreign-body reaction(J Exp Med,2002). Depletion of the fibroblasts that surround the carcinogens can induce the variation of the type of tumor induced by a same carcinogen(Cancer Research,2013). Besides, upon the stimulation of foreign bodies, fibroblasts can secrete MCP-1 to recruit macrophages into injured tissues, to promote local inflammation and tumor formation(Am J Pathol, 2011)

Biography
  Research Interest :

Inflammation in tumor microenvironment

Research Interest
Prof. Ying Wan

Prof. Ying Wan
Professor
Institute of Immunology
Third Military Medical University
China

  Biography :

He is well versed with molecular cloning, siRNA, lentivirus production and bioinformatics. He is having expertise in Enzyme Linked Immunosorbent Assay (ELISA), Flow cytometry techniques, Polymerase chain reaction, Western blotting. He also has expertise in Confocal microscopy, Spining disk microscopy

Biography
  Research Interest :

Cellular mechanism of antigen presentation of dendritic cell, Innate immunology, Vaccine

Research Interest
Prof. Xiaohuan Guo

Prof. Xiaohuan Guo
Professor
Principal Investigator, School of Medicine
Tsinghua University
China

  Biography :

The gut mucosal immune system not only protects us from numerous pathogen invasion, but also maintains the homeostasis with commensal bacteria and innocuous food antigens. The failure of gut homeostasis not only increases the risk of gut infection, inflammatory bowel disease, but is also related to allergy, cancer,autoimmune, and metabolic diseases.Our lab’s goal is to combine molecular data with in vivo models to further the understanding of mechanisms underlying these homeostatic and pathological conditions and aid in the development of treatments for these gut related diseases.

Biography
  Research Interest :

Mucosal immunology, innate lymphoid cells, microbiota, gut related diseases

Research Interest
Prof. Woong-Kyung Suh

Prof. Woong-Kyung Suh
Professor
Director, Immune Regulation Research Unit, IRCM
Department of Medicine (accreditation in microbiology, infectiology and immunology, and for the Molecular Biology Programs), Université de Montréal
Canada

  Biography :

Dr. Woong-Kyung Suh is Director of Immune Regulation Research Unit at IRCM (Institut de recherches cliniques de Montréal), Associate Research Professor at University of Montreal, and Adjunct Professor at McGill University. Dr. Suh’s main research interest isto understand signal transduction pathways of T follicular helper (Tfh) and T follicular regulatory (Tfr) cells in health and disease using gene-targeted mouse models. T cell costimulatory receptors and their downstream signaling molecules play important roles in generation and function of Tfh/Tfr cells and they are also suspected to support progression of Tfh-derived peripheral T cell lymphoma AITL (angioimmunoblastic T cell lymphoma). Dr. Suh’s laboratory has identified phosphoinositide 3-kinase as one of the key Tfh signaling components. Expanding on thisfinding, Dr. Suh’s group continues to work on CD28 and SLAM family costimulatory receptors and their downstream adaptor proteins, kinases, and transcription factors that control follicular T cells. The long-term goal of Dr. Suh’s research is to develop knowledge-based innovative treatment options for antibody-associated immunological disorders and AITL.

Biography
  Research Interest :

Signaling transduction mechanisms in T follicular helper cell generation and function; Role of T cell costimulation in tumor progression of angioimmunoblastic T cell lymphoma (AITL); Role of B7 family costimulation in anti-tumor T cell immunity

Research Interest
Prof. Junfei Jin, MD, PhD

Prof. Junfei Jin, MD, PhD
Professor
Executive Director of Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair
Director of Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University
China

  Biography :

Prof. Junfei Jin is the Executive Director of Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair (China). He is also the Head of Central Lab, Affiliated Hospital of Guilin Medical University (China). He is also appointed as the Director of Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University (China), Oncology Academic Leader of Guilin Medical University (China)

Biography
  Research Interest :

signaling pathways (sphingolipid, Toll-like receptor, and apoptosis) and related disease (liver diseases and Diabetes).

Research Interest
Dr. Avery Posey

Dr. Avery Posey
Instructor
Center for Cellular Immunotherapies
University of Pennsylvania, Philadelphia, PA
USA

  Biography :

Dr. Avery Posey is an immunologist with training in bioinformatics, biochemistry, and molecular and developmental genetics. He completed his postdoctoral training in the Center for Cellular Immunotherapies at the University of Pennsylvania with Dr. Carl H. June investigating novel CAR T cells for solid tumors; CAR T cell costimulation, signaling and metabolism; and cancer-specific glycosylation. Dr. Posey’s work was the first to target the combination of abnormal glycosylation and tumor-associated antigens as a method to avoid off-tumor, on-target toxicities. His laboratory focuses on the development of glycan-specific adoptive cell therapies for the treatment of metastatic and advanced cancers, as well as methods to improve the efficacy and impact of current cellular therapies, including gene editing and overcoming T cell exhaustion.

Biography
  Research Interest :

1) Cancer-specific glycosylation, 2) Costimulation, metabolism and signaling of CAR T cells and other adoptive immunotherapies, 3) Gene editing of engineered T cell therapies, 4) Comparative medicine oncoimmunology

Research Interest
Dr. Guangfu Li, PhD & DVM

Dr. Guangfu Li, PhD & DVM
Assistant Professor
Department of Surgery
University of Missouri-Columbia
USA

  Biography :

Dr. Guangfu Li was trained as a postdoctoral fellow at the Penn State Hershey Medical Center with Drs. Kevin F. Staveley-O’Carroll, David X. Liu, and Channe Gowda. His research has focused on cancer biology, cancer immunology, and clinically available therapeutic strategies for cancer. Using a cyclic amplification and selection of targets (CASTing) approach, online Transcription Element Search System (TESS), double immunoprecipitation (IP), and mass spectrometry, Dr. Li and his colleagues investigated role of activating transcriptional factor 5 (ATF5) in regulating cell growth and promoting cancer cell-specific survival. The studies identified ATF5 downstream targets, ATF5-interacting partner proteins, and role of ATF5 in the interaction between mother centriole and pericentriolar material (PCM).Using immunocompetent mice, Dr. Li and his colleagues establishedclinically relevant murine model for different cancers including hepatocellular cancer and pancreatic cancer. Using these models, theyhave explored different ways to overcome tumor-induced immunotolerance and develop immune-basedcombinational therapies to eliminate the established tumors. In addition, his team uses different technologies to detect the circulating tumor cells (CTCs) in cancer patients toward development of effective strategies against tumor metastasis.

Biography
  Research Interest :

Tumor-inducedimmunotolerance; Immune-based therapeutic strategies against cancer; animal models of cancer; Circulating tumor cells (CTCs); Circulating tumor DNA (ctDNA)

Research Interest
Dr. Erica L. Stone, Ph.D.

Dr. Erica L. Stone, Ph.D.
Assistant Professor
Translational Tumor Immunology Program
The Wistar Institute, Philadelphia
USA

  Biography :

I am an Assistant Professor in the Translational Tumor Immunology Program at The Wistar Institute. During my Ph.D. I studied glycoimmunology. My postdoctoral training was in a classical immunology lab. As a Postdoctoral Fellow in the Laboratory of Stephen M. Hedrick at the University of California San Diego I studied the role of FOXO transcription factors in regulating T helper cell development and function. Our research showed that FOXO1 controls the expression of CTLA--‐4, and ICOS; is required for T regulatory cell function; and inhibits Th1 and T follicular helper cell differentiation and effector molecules. In the Stone laboratory we are investigating immune suppression in the tumor microenvironment and mechanisms of resistance to immunotherapies.

Biography
  Research Interest :

T cells, Regulatory T cells, Tregs, T cell differentiation, T helper cells, T cell suppression, CTLA-4, immune checkpoint inhibitors, FOXO1, immunotherapy, tumor immunology, glycobiology, glyco-immunology, lectins, and the tumor microenvironment.

Research Interest
Prof. Xiang-Yang (Shawn) Wang, Ph.D.

Prof. Xiang-Yang (Shawn) Wang, Ph.D.
Professor
Department of Human & Molecular Genetics
Virginia Commonwealth University School of Medicine
USA

  Biography :

Biography
  Research Interest :

Myeloid cells, antigen presentation, tumor immunology and immunotherapy.

Research Interest
Dr. Xiao Chen MD, PhD

Dr. Xiao Chen MD, PhD
Assistant Professor
Division of Hematology and Oncology
Medical College of Wisconsin
USA

  Biography :

Dr. Xiao Chen is Assistant Professor of Medicine at the Medical College of Wisconsin (MCW), Division of Hematology and Oncology. Dr. Chen's current research focuses on graft-versus-host disease (GVHD), which is a serious, frequently fatal complication following allogeneic hematopoietic stem cell transplantation. Specifically, he is investigating the role of the retinoic acid pathway in the pathophysiology of GVHD. He also has a strong interest in tumor immunology and immunotherapy. His long-term research goal is to find ways to augment the beneficial graft-versus-tumor (GVT) effect while minimizing GVHD in order to make allogeneic hematopoietic stem cell transplantation a more effective and safer treatment for cancer patients.

Biography
  Research Interest :

Transplantation Immunology, Graft-versus-Host Disease, Tumor Immunology and Immunotherapy

Research Interest
Dr. Antonio Di Loria, DVM, DrSc,

Dr. Antonio Di Loria, DVM, DrSc,
Assistant Professor
Department of Experimental and Clinical Medicine
University Magna Græcia of Catanzaro
Italy

  Biography :

Dr. Di Loria graduated from the University of Napoli “Federico II” Faculty of Veterinary Medicine in 2000 and attended for 2 years as intern to Section of Internal Medicine, under the mentorship of Prof. Paolo Ciaramella. In 2005 after three years, focused on small animal Internal Medicine, he obtained a Reseach Doctorate (DrSc) conducing a research centered on the role of thrombomodulin, protein C and antithrombin in cats affected by cardiomyopaties. Then he obtained a postdoctoral fellowship focusing on the immunological and therapeutic aspects of Leishmania infection in dogs. In November 2011 he become Assistant Professor of Small Animal Internal Medicine at Department of Health Sciences University Magna Græcia of Catanzaro Italy.

Biography
  Research Interest :

His research interests include canine leishmaniosis, cardiologicalbiomarkers, clinical aspect ofparasitosis, disorders of hemostasis and clinical immunology during infectious diseases. In particular, he is interested in the role of skin and innate immunity during Leishmania infection in dog. He also studied the role of Regulatory T cells, Cytotoxic T lymphocytes and a Th1 cytokine profile in dogs naturally infected by Leishmaniainfantum. Moreover he studied the presence of anti-plateletIgM and IgGantibodies in dogs naturallyinfected by Leishmaniainfantum. Recently he focuses his interest on exosomes and microRNAs and their role in immunologic field during leishmania infection and dermatologic diseases in dogs.

Research Interest